Biotage Makes a Change in Top Management after Business Area President Resigns
News Feb 28, 2006
Biotage has announced the change in its top management. David Patteson, President of the business area Discovery Chemistry has decided to seek new challenges elsewhere. He will leave the company on 1 April 2006.
David Patteson has been with Biotage for seven years during which time he has successfully built up the Global operations. In the last years he also led the integration of the acquired companies and the cost reductions that followed.
The forthcoming CEO of Biotage, Torben Jorgensen, will take over Mr Patteson's responsibilities with immediate effect and work alongside him until 1 April.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE